One paper appears repeatedly in discussions about gold nanoparticles and the brain. Its published title is striking: Treatment with isolated gold nanoparticles reverses brain damage caused by obesity.
The study is real, but its title can sound much broader than the experiment itself.
The researchers used synthesised gold nanoparticles averaging 18 nanometres in size and administered them intraperitoneally to mice. They studied an obesity model and measured inflammatory, oxidative-stress, metabolic and mitochondrial markers.
The study did not test an oral consumer colloidal-gold product, did not involve humans and did not demonstrate recovery from stroke, traumatic brain injury, dementia or another clinical neurological condition.
What it did show is still scientifically interesting: selected markers associated with obesity-related inflammation and oxidative stress improved, while other abnormalities, including mitochondrial dysfunction, did not.
Quick Answer: What Did the Mouse Study Find?
A 2021 mouse study found that 18 nm gold nanoparticles improved several inflammatory and oxidative-stress markers in an obesity model. The particles were administered by intraperitoneal injection once daily for 14 days.
The treatment also reduced food intake and improved elevated glucose in the obese mice. However, it did not reduce body or mesenteric fat weight, did not correct the lipid profile and did not reverse mitochondrial dysfunction.
The study therefore supports further research into specific engineered gold nanoparticle systems. It does not establish that drinking colloidal gold reverses brain damage or treats neuroinflammation in humans.
For the broader evidence around cognition, neurogenesis, brain energy and clinical nanogold research, see Colloidal Gold and the Brain: What Does the Science Say?.
What the Researchers Actually Tested
The paper described two experiments in mice.
| Study element | What was tested | Why it matters |
|---|---|---|
| Particle | Synthesised gold nanoparticles averaging 18 nm. | Findings apply to this experimental nanoparticle preparation, not automatically to other gold products. |
| Species | Mice. | Animal findings require human studies before clinical treatment claims can be made. |
| Route | Intraperitoneal administration. | This bypasses the digestive route used by an oral colloidal-gold product. |
| Obesity model | Mice fed a high-fat diet were compared with controls. | The experiment investigated obesity-associated metabolic and inflammatory changes. |
| Treatment period | Once daily for 14 days in the obesity experiment. | This was a short preclinical intervention, not long-term human supplementation. |
| Outcomes | Inflammation, oxidative stress, mitochondrial function, glucose, lipids, food intake and body/fat weight. | The paper measured biological markers rather than human cognition, symptoms or neurological recovery. |
Experiment One: Tissue Distribution and Short-Term Safety Markers
In the first experiment, the researchers synthesised and characterised 18 nm gold nanoparticles and administered them alone or with sodium diclofenac and/or soy lecithin.
The animals received the preparations once daily for either one day or fourteen days. The investigators then measured gold nanoparticle concentrations in tissues and assessed alanine aminotransferase and creatinine as markers related to liver and kidney injury.
They reported greater tissue accumulation after 14 days and no signs of hepatic or renal damage according to the specific biochemical measurements used in that experiment.
That is a limited preclinical safety observation. It does not establish that all gold nanoparticles, doses, routes or long-term consumer products are safe.
Experiment Two: Obesity, Brain Inflammation and Biochemistry
In the second experiment, mice were fed either a high-fat diet or a control diet. After eight weeks, the animals received saline or 18 nm gold nanoparticles once daily for 14 days.
The PubMed abstract reports the experimental gold nanoparticle preparation at 70 mg/L, with 70 mg/kg also stated in the dosing description. Because the published abstract presents both units, the most important point for interpreting the consumer relevance is not to convert or reinterpret them, but to recognise that this was a defined injected research preparation rather than an oral supplement.
At the end of the experiment, the researchers assessed serum glucose and lipids, mesenteric fat, inflammatory markers, oxidative-stress measures and mitochondrial function in brain tissue.
What Improved in the Obese Mice?
Inflammatory Parameters
The authors reported beneficial effects on inflammatory parameters in the obesity model. Obesity is associated with chronic low-grade inflammatory signalling, and metabolic inflammation can influence multiple tissues including the brain.
This is evidence of an effect in a specific mouse model. It is not evidence that a consumer colloidal-gold product treats human neuroinflammation.
Oxidative-Stress Parameters
The researchers also reported improvements in oxidative-stress measures. Oxidative stress reflects an imbalance between reactive molecules and protective cellular systems and is widely studied in metabolic and neurological disease.
Glucose
The paper reports that elevated glucose levels in the obese animals were reversed following gold nanoparticle treatment. This was a metabolic outcome within the mouse model, not evidence of cognitive improvement or a human diabetes treatment effect.
Food Intake
Food intake fell in the treated obese mice. This should not be converted into an appetite-suppression or weight-loss claim for consumer colloidal gold.
What Did Not Improve?
The negative findings are essential to understanding the paper.
Mitochondrial Dysfunction Was Not Reversed
The authors specifically state that the beneficial effects on inflammation and oxidative stress occurred without reverting mitochondrial dysfunction.
Body and Mesenteric Fat Weight Did Not Fall
Gold nanoparticle administration did not reduce body weight or mesenteric fat weight in the obese animals.
The Lipid Profile Was Not Corrected
The lipid profile was not altered in a way that would support a broad claim that the intervention reversed the metabolic effects of obesity.
These findings show why the phrase “reverses brain damage” should not be read as complete biological restoration.
What Does “Reverses Brain Damage” Mean in This Paper?
The phrase comes from the authors' published title. The measured outcomes, however, were much more specific.
The researchers found improvements in selected inflammatory, oxidative-stress and metabolic measures associated with their obesity model. They did not demonstrate recovery from a diagnosed human brain injury or neurodegenerative disease, and they did not measure a clinical neurological recovery endpoint.
A more precise summary is:
In obese mice, intraperitoneally administered 18 nm gold nanoparticles improved selected inflammation, oxidative-stress and metabolic markers, while mitochondrial dysfunction and several other obesity-related abnormalities remained.
That is a meaningful preclinical finding without turning the paper into a claim it did not test.
Particle Size Can Change the Inflammatory Response
Gold nanoparticles should not be treated as one biologically uniform substance.
A separate mouse study investigated 5, 20 and 50 nm gold nanoparticles and measured pro-inflammatory cytokine gene expression in brain tissue. A single injection of 5 nm particles significantly increased IL-1β and IL-6 expression at day seven, while 20 and 50 nm particles did not produce the same significant change.
The authors concluded that particle size played an important role in the immune response.
This is an important counterpoint to simplistic claims that “gold nanoparticles reduce inflammation”. Depending on size, coating, dose, route and experimental context, different nanoparticle systems can produce different and sometimes opposite biological responses.
Read the size-dependent mouse brain inflammation study on PubMed.
How This Fits With Wider Brain Research
Other animal and laboratory studies have investigated gold nanoparticles in cerebral inflammation, ischemia, sepsis and neurodegenerative disease models. Some systems have produced anti-inflammatory or neuroprotective signals, while others have produced pro-inflammatory effects.
For example, 20 nm citrate-coated gold nanoparticles reduced several inflammatory changes in cerebral microvessels in a mouse model of sepsis. In a rat cerebral ischemia-reperfusion model, 20 nm particles showed anti-inflammatory and anti-apoptotic effects while 5 nm particles behaved differently.
These experiments strengthen one broad conclusion: particle engineering matters. They do not establish a universal therapeutic effect for gold itself.
Mouse sepsis and cerebral microvessel study
Rat cerebral ischemia-reperfusion study.
For a wider evidence map, visit the Gold Nanoparticles Research Library.
Engineered Gold Nanoparticles Are Not Automatically the Same as Oral Colloidal Gold
The term gold nanoparticle covers a broad family of materials. Researchers can alter particle diameter, shape, surface charge, coatings, aggregation behaviour, concentration and route of administration.
Those variables can change tissue distribution, cellular uptake, immune response and clearance.
The 2021 obesity study used 18 nm synthesised particles delivered intraperitoneally. An oral colloidal-gold product instead passes through the gastrointestinal system, where absorption and biological exposure can differ substantially.
That is why the mouse study cannot be used as proof that drinking colloidal gold produces the same brain effects.
For the basic distinction between consumer colloids and engineered research systems, see What Is Colloidal Gold?.
What Has Been Studied in Commercial Colloidal Gold?
A 2026 study directly analysed commercially available colloidal-gold dietary supplements intended for oral consumption. Products labelled at 30, 55 and 110 mg/L were examined, and the products tested contained metallic gold nanoparticles with reported particle sizes of approximately 4 to 11 nm.
The researchers also performed preliminary cell-based biological assessments and found responses that varied by cell type. They emphasized the need for further toxicological work.
Crucially, this study did not test brain inflammation, cognition, memory or obesity-related neurological outcomes.
Its relevance is methodological: commercial oral colloidal-gold products are beginning to be studied directly, which is preferable to assuming that results from an injected engineered nanoparticle automatically apply to a supplement.
How Strong Is the Evidence?
| Evidence | What it shows | What it does not show |
|---|---|---|
| 2021 obesity mouse study | Injected 18 nm AuNPs improved selected inflammatory, oxidative-stress and metabolic markers. | Does not show oral colloidal gold reverses brain damage in humans. |
| Particle-size mouse study | 5 nm particles increased selected pro-inflammatory cytokine expression in brain tissue while larger particles behaved differently. | Does not mean every small or large gold nanoparticle behaves identically in every model. |
| Other animal neuroinflammation studies | Specific engineered AuNP systems can alter inflammatory pathways in sepsis and ischemia models. | Does not establish a general gold treatment for neurological disease. |
| 2026 commercial supplement study | Confirmed nanoscale metallic gold in the specific oral products tested and performed preliminary cell assays. | Did not test brain inflammation or cognitive outcomes in people. |
| Consumer colloidal gold for brain inflammation | No established direct clinical evidence from this research set. | The mouse findings cannot be transferred directly to a retail oral product. |
Key Takeaways
- The 2021 paper used 18 nm gold nanoparticles in obese mice.
- The particles were administered intraperitoneally, not orally.
- Inflammatory and oxidative-stress markers improved.
- Glucose improved and food intake fell in the model.
- Mitochondrial dysfunction was not reversed.
- Body and mesenteric fat weight did not fall.
- Other mouse studies show that particle size can materially change inflammatory responses.
- The study does not demonstrate that consumer colloidal gold reverses brain damage or treats brain inflammation in humans.
Frequently Asked Questions
Did gold nanoparticles reverse brain damage in the 2021 study?
The paper's title uses that phrase, but the experiment measured selected inflammatory, oxidative-stress, metabolic and mitochondrial outcomes in obese mice. Several markers improved, while mitochondrial dysfunction and other abnormalities did not. It was not a human brain-injury trial.
Were the gold nanoparticles taken orally?
No. The 18 nm nanoparticles were administered intraperitoneally to mice, which is a different exposure route from drinking colloidal gold.
Does the study prove colloidal gold reduces brain inflammation in humans?
No. It is preclinical animal research using a specific nanoparticle preparation. Human clinical evidence would be needed before making that treatment claim.
Did the gold nanoparticles repair mitochondrial dysfunction?
No. The authors reported improvements in inflammation and oxidative stress without reversing mitochondrial dysfunction.
Can gold nanoparticles sometimes increase inflammation?
Yes, depending on the system. In one mouse brain study, 5 nm particles increased IL-1β and IL-6 gene expression while 20 and 50 nm particles did not show the same significant effect. This illustrates why particle size and formulation matter.
Has commercial colloidal gold been studied directly?
Yes. A 2026 study analysed several commercial oral colloidal-gold products and confirmed metallic gold nanoparticles in the specific products tested. It did not test brain inflammation, memory or cognition.
Scientific References
- Prá M, Ferreira GK, de Mello AH, et al. Treatment with isolated gold nanoparticles reverses brain damage caused by obesity. Mater Sci Eng C Mater Biol Appl. 2021;120:111392. PubMed PMID 33545808.
- Khan HA, Alamery S, Ibrahim KE, et al. Size and time-dependent induction of proinflammatory cytokines expression in brains of mice treated with gold nanoparticles. Saudi J Biol Sci. 2019;26(3):625-631. PubMed PMID 30899181.
- Gold nanoparticles reduce inflammation in cerebral microvessels of mice with sepsis. 2021. PubMed PMID 33608025.
- An intrinsic therapy of gold nanoparticles in focal cerebral ischemia-reperfusion injury in rats. PubMed PMID 23858966.
- Chiang MC, Yang YP, Nicol CJB, Wang CJ. Gold Nanoparticles in Neurological Diseases: A Review of Neuroprotection. Int J Mol Sci. 2024;25(4):2360. PubMed PMID 38397037.
- Bute OC, Gheboianu AI, Neacsu A, et al. Colloidal Gold Dietary Supplements as Nanomaterials: Physicochemical Evaluation, Estimated Oral Exposure, and Preliminary Biological Assessment. Int J Mol Sci. 2026;27(13):5872. PubMed PMID 42450145.
